168 related articles for article (PubMed ID: 37888623)
1. Exploring the Interplay between the Clinical and Presumed Effect of Botulinum Injections for Cervical Dystonia: A Pilot Study.
Hefter H; Samadzadeh S
Toxins (Basel); 2023 Sep; 15(10):. PubMed ID: 37888623
[TBL] [Abstract][Full Text] [Related]
2. The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia.
Hefter H; Schomaecker I; Schomaecker M; Rosenthal D; Samadzadeh S
Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357965
[TBL] [Abstract][Full Text] [Related]
3. Lessons about Botulinum Toxin A Therapy from Cervical Dystonia Patients Drawing the Course of Disease: A Pilot Study.
Hefter H; Schomaecker I; Schomaecker M; Ürer B; Brauns R; Rosenthal D; Albrecht P; Samadzadeh S
Toxins (Basel); 2023 Jun; 15(7):. PubMed ID: 37505701
[TBL] [Abstract][Full Text] [Related]
4. The impact of the initial severity on later outcome: retrospective analysis of a large cohort of botulinum toxin naïve patients with idiopathic cervical dystonia.
Hefter H; Samadzazeh S; Rosenthal D
J Neurol; 2021 Jan; 268(1):206-213. PubMed ID: 32761340
[TBL] [Abstract][Full Text] [Related]
5. The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation-A Monocentric Cross-Sectional Pilot Study.
Hefter H; Schomaecker I; Schomaecker M; Rosenthal D; Samadzadeh S
Medicina (Kaunas); 2022 Jan; 58(1):. PubMed ID: 35056396
[No Abstract] [Full Text] [Related]
6. No Secondary Treatment Failure during Incobotulinumtoxin-A Long-Term Treatment Demonstrated by the Drawing of Disease Severity.
Hefter H; Brauns R; Ürer B; Rosenthal D; Albrecht P; Samadzadeh S
Toxins (Basel); 2023 Jul; 15(7):. PubMed ID: 37505723
[TBL] [Abstract][Full Text] [Related]
7. Study protocol: multimodal physiotherapy as an add-on treatment to botulinum neurotoxin type A therapy for patients with cervical dystonia: DysPT-multi-a prospective, multicentre, single-blind, randomized, controlled study.
Werner C; Loudovici-Krug D; Derlien S; Rakers F; Smolenski UC; Lehmann T; Best N; Günther A
Trials; 2021 Oct; 22(1):740. PubMed ID: 34696821
[TBL] [Abstract][Full Text] [Related]
8. Cervical dystonia: factors deteriorating patient satisfaction of long-term treatment with botulinum toxin.
Marciniec M; Szczepańska-Szerej A; Rejdak K
Neurol Res; 2020 Nov; 42(11):987-991. PubMed ID: 32693754
[TBL] [Abstract][Full Text] [Related]
9. The clinical utility of botulinum toxin injections targeted at the motor endplate zone in cervical dystonia.
Delnooz CC; Veugen LC; Pasman JW; Lapatki BG; van Dijk JP; van de Warrenburg BP
Eur J Neurol; 2014 Dec; 21(12):1486-e98. PubMed ID: 25060697
[TBL] [Abstract][Full Text] [Related]
10. Quality of life in long-term botulinum toxin treatment of cervical dystonia: Results of a cross sectional study.
Moll M; Rosenthal D; Hefter H
Parkinsonism Relat Disord; 2018 Dec; 57():63-67. PubMed ID: 30150129
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal.
Marsili L; Bologna M; Jankovic J; Colosimo C
Expert Opin Drug Saf; 2021 Jun; 20(6):695-705. PubMed ID: 33831328
[No Abstract] [Full Text] [Related]
12. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
13. Targeting pain in the long-term treatment of cervical dystonia with botulinum toxin A.
Marciniec M; Szczepańska-Szerej A; Papuć E; Rejdak K
Int J Neurosci; 2022 Oct; 132(10):1026-1030. PubMed ID: 33295845
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin type A and cervical dystonia: a seven-year follow-up.
Camargo CH; Teive HA; Becker N; Munhoz RP; Werneck LC
Arq Neuropsiquiatr; 2011 Oct; 69(5):745-50. PubMed ID: 22042174
[TBL] [Abstract][Full Text] [Related]
15. Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis.
Hefter H; Spiess C; Rosenthal D
J Neural Transm (Vienna); 2014 May; 121(5):513-9. PubMed ID: 24311063
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia.
Ferreira JJ; Colosimo C; Bhidayasiri R; Marti MJ; Maisonobe P; Om S
Parkinsonism Relat Disord; 2015 Feb; 21(2):111-5. PubMed ID: 25499753
[TBL] [Abstract][Full Text] [Related]
17. "Pseudo"-Secondary Treatment Failure Explained via Disease Progression and Effective Botulinum Toxin Therapy: A Pilot Simulation Study.
Hefter H; Rosenthal D; Samadzadeh S
Toxins (Basel); 2023 Oct; 15(10):. PubMed ID: 37888649
[TBL] [Abstract][Full Text] [Related]
18. A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia.
Hu W; Rundle-Gonzalez V; Kulkarni SJ; Martinez-Ramirez D; Almeida L; Okun MS; Wagle Shukla A
Parkinsonism Relat Disord; 2019 Jun; 63():195-198. PubMed ID: 30837195
[TBL] [Abstract][Full Text] [Related]
19. Subjective versus objective symptom intensities ratings in cervical dystonia and hemifacial spasm across a botulinum neurotoxin cycle.
Wöllner J; Weise D; Leplow B
Brain Behav; 2021 Mar; 11(3):e02023. PubMed ID: 33403834
[TBL] [Abstract][Full Text] [Related]
20. Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia.
Comella C; Ferreira JJ; Pain E; Azoulai M; Om S
J Neurol; 2021 Mar; 268(3):903-912. PubMed ID: 32939574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
